Lupin receives USFDA approval for generic Ravicti oral liquid

Approval expands Lupin’s specialty portfolio in the US market for treatment of urea cycle disorders

Lupin launches authorized generic of Ravicti in US

The product is indicated for the chronic management of patients with Urea Cycle Disorders

NIFTY Pharma remains resilient amid mixed market sentiment

Pharma and healthcare stocks stay in focus as investors track earnings, USFDA approvals, hospital growth, and global market pressures

Aurobindo Pharma bags USFDA nod for Glycerol Phenylbutyrate Oral Liquid

The approved product is a generic version of Ravicti, originally developed and marketed by Horizon Therapeutics

Aurobindo Pharma wins USFDA nod for rare disease drug set for immediate launch